The effect of atorvastatin on lung function and morbidity as add-on therapy in asthmatic patients. A double-blind randomized cross-over trial.

The effect of atorvastatin on lung function and morbidity as add-on therapy in normolipid asthmatic patients. A double-blind placebo controlled randomized cross-over trial.

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12607000179437

Enrollment

Registered

2007-03-22

Start date

2006-10-20

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The main goal of the study was to assess the effects of atorvastatin on asthma as an inflammatory disease.

Interventions

atorvastatin 10 mg per day oral for one month or placebo oral for one month, each therapy separated with 2 weeks wash out period (cross-over)

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

16 Years to 65 Years

Healthy volunteers

Inclusion criteria

Persistent moderate to severe asthma

Exclusion criteria

Dyslipidemia, adverse effect due to atorvastatin, other comorbid condition (heart failure, diabetes, MI, hypertension), receiving medication(s) interact with atorvastatin.

Outcome results